
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
This publication highlights expert perspectives on the current therapeutic landscape in chronic lymphocytic leukemia with emphasis on factors affecting treatment selection including novel regimens, combination therapies, and ongoing clinical trials.